Reagents and methods for imaging cancers expressing pdgfralpha
AssigneesTelix Pharmaceuticals (Innovations) Pty Ltd., Eli Lilly and Company
InventorsMichael Paul Wheatcroft, Alesia Ivashkevich, Corinne Letendre, Rodney John Hicks, Tracey Jean Brown, Neel Jagdish Patel, Angela Man Yin Hong
Life of this patent
Estimating the term…
Abstract
The invention relates to reagents for in vivo imaging and detection of cancers that express platelet derived growth factor receptor alpha (PDGFRalpha) using an olaratumab antibody, and methods of use thereof including methods for imaging cancers and methods for selecting patients for treatment.
Claims49
An olaratumab antibody or olaratumab antibody bioconjugate, suitable for radiolabelling with a diagnostic radioisotope.
An olaratumab antibody or antigen binding fragment thereof, conjugated to a radioisotope suitable for in vivo imaging, for:
- the detection or imaging of PDGFRalpha-expressing tumours in a subject;
- for the diagnosis of a PDGFRalpha-expressing cancer in a subject;
- for producing an image of a PDGFRalpha-expressing cancer in a subject;
- for classifying a cancer as sensitive to treatment with a PDGFRalpha-inhibitor;
- for classifying or selecting a patient for eligibility for cancer therapy with an inhibitor of PDGFRalpha;
- or
- for monitoring the response to treatment of a PDGFRalpha-expressing cancer or a subject having a PDGFRalpha-expressing cancer.
Dependencies are inferred from the claim text.